CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
A double-blind, randomized, placebo-controlled video capsule endoscopy trial on the safety and efficacy of Rifaximin-EIR 800 mg BID to prevent intestinal injury caused by a two-weeks-treatment of diclofenac SR 75 mg BID plus omeprazole 20…
DOI 10.1055/s-0035-1551703
Bibliografische Angaben
Nachweis in CareLit
Autor:innenW Dolak, C Scarpignato, A Lanas, P Matzneller, M Fogli, M Grimaldi, M Zeitlinger, I Bjarnason
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Proton pump inhibitors (PPIs) may worsen non-steroidal anti-inflammatory drug (NSAID) induced enteropathy by impairing the intestinal microbiota. Rifaximin is an antimicrobial drug which covers a broad spectrum of enteric pathogens. The aim of this study was to evaluate the safety and efficacy of Rifaximin-EIR, a delayed-release formulation of coated microgranules of rifaximin, to prevent small bowel les…
Zitieren
Zitierempfehlung
W Dolak, C Scarpignato, A Lanas, P Matzneller, M Fogli, M Grimaldi, M Zeitlinger, I Bjarnason (2015) A double-blind, randomized, placebo-controlled video capsule endoscopy trial on the safety and efficacy of Rifaximin-EIR 800 mg BID to prevent intestinal injury caused by a two-weeks-treatment of diclofenac SR 75 mg BID plus omeprazole 20 mg OD in 60 healthy volunteers. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0035-1551703
Mit CareLit weiterarbeiten